| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/16/2003 | US20030012832 Bioactivity of methyl palmitate obtained from a mangrove plant Salvadora persica L |
| 01/16/2003 | US20030012831 Liquid-liquid extraction being carried out in the first stage at a pH-value of about 4; treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence. |
| 01/16/2003 | US20030012830 Acetone, a salicylate-based compound and an emollient. |
| 01/16/2003 | US20030012827 May be administered in a purified form, or as part of a larger molecule, such as a glyceride that may be mixed, which releases free fatty acid after ingestion |
| 01/16/2003 | US20030012826 Carotenoids; vitamins E, D, & C; thiamine; riboflavin; niacin; folic acid; pyridoxine; biotin; pantothenic acid; cobalamin; magnesium; manganese; zinc; selenium; chromium; copper; alpha lipoic acid; and lutein; added iron free |
| 01/16/2003 | US20030012820 Less than 30 % of the particles exhibit a particle size of greater than 425 micrometers and greater than 80 % of the particles exhibit a particle size of greater than 45 micrometers; improved robustness and flexibility |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012817 Modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. |
| 01/16/2003 | US20030012814 At least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. |
| 01/16/2003 | US20030012812 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| 01/16/2003 | US20030012803 E.g., ethyl 3-methyl-5-(,5,8,8-tetra-methyl-5,6,7,8-tetra-hydronaphthalen-2 -ylselenyl)pent-2-en-4-ynoate; dermatological, rheumatic, respiratory, cardiovascular and ophthalmological uses as well as cosmetic uses |
| 01/16/2003 | US20030012793 Purified complex of heat shock protein noncovalently bound to a molecule. |
| 01/16/2003 | US20030012784 Methods for treatment of inflammatory diseases |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012774 Mixture of gamma-cyclodextrin and coenzyme Q1O is treated by homogenisation and inputting energy. |
| 01/16/2003 | US20030012773 Diaper dermatitis preventative medication and a method for making and using same |
| 01/16/2003 | US20030012763 Mixture containing the ammonium quat in a solvent that includes at least one glycol and at least one fatty alcohol, wherein said raw material composition has cationic activity of over 35%; improved transportation efficiency |
| 01/16/2003 | US20030012749 Applying a preparation comprising water, urea and a film-forming agent to remove and treat diseased nails affected by onychomycosis |
| 01/16/2003 | US20030012742 Porous particles comprising excipients for deep lung delivery |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012739 Containing rosiglitazone maleate and a fluid carrier. |
| 01/16/2003 | US20030012738 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | US20030012736 Methods of treating lung inflammation |
| 01/16/2003 | DE20210068U1 Externally applied emulsion for treating skin irritation, eczema, wound sites or injuries, containing synergistic combination of emu oil and beta-glucan or derivative |
| 01/16/2003 | CA2521993A1 Crystalline forms of ¬r-(r*,r*)|-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-¬(phenylamino)carbonyl|-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 01/16/2003 | CA2490386A1 Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist |
| 01/16/2003 | CA2471232A1 Calcium l-threonate for preventing or treating bone fracture |
| 01/16/2003 | CA2471151A1 Calcium l-threonate for preventing or treating cartilage related diseases |
| 01/16/2003 | CA2454613A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | CA2454544A1 Optic nerve protecting agents containing .alpha.1 receptor blocker as active ingredient |
| 01/16/2003 | CA2453572A1 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction |
| 01/16/2003 | CA2452874A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452872A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452686A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | CA2452646A1 Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatement ofurinary incontinence |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452603A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | CA2452597A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | CA2452592A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | CA2452590A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | CA2452401A1 Process for producing fat comprising triglyceride containing highly unsaturated fatty acid |
| 01/16/2003 | CA2452392A1 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | CA2452372A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | CA2452366A1 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | CA2452211A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as gaba-a receptor ligands |
| 01/16/2003 | CA2451983A1 Compounds used to treat alcoholism |
| 01/16/2003 | CA2451749A1 Novel immunomodulating compounds |
| 01/16/2003 | CA2451742A1 Treatment of parasitic disease |
| 01/16/2003 | CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| 01/16/2003 | CA2451606A1 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | CA2451391A1 C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| 01/16/2003 | CA2451360A1 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | CA2451055A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | CA2450857A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/16/2003 | CA2450821A1 New use of a pyridazinone derivative |
| 01/16/2003 | CA2449828A1 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | CA2448913A1 Sulfone containing bicyclic aromatic ring compounds, their preparation and use as nicotinic acetyl-chloine receptors |
| 01/16/2003 | CA2447886A1 Compositions for removing human cerumen |
| 01/16/2003 | CA2394010A1 Novel n-benzylpiperazine derivatives, their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275733A2 Assay methods for peptidase modulators |
| 01/15/2003 | EP1275647A1 Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275646A1 Indolylpyrrole derivatives and cell death inhibitors |
| 01/15/2003 | EP1275644A1 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275641A2 Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275638A1 Combination therapy for the treatment of immunological disorders |
| 01/15/2003 | EP1275635A1 Calcium receptor-active compounds |
| 01/15/2003 | EP1275399A2 Method and preparation for preventing and/or treating vascular disorders and secondary disorders associated therewith |
| 01/15/2003 | EP1275397A2 Medicament for local use |
| 01/15/2003 | EP1275395A2 Use of hyaluronic acid for preparing a composition for vaginal use |
| 01/15/2003 | EP1275394A2 Ultra low dose oral contraceptives with sustained efficacy that induces amenorrhea |
| 01/15/2003 | EP1275393A1 Pharmaceutical formulation containing pteridine derivative |
| 01/15/2003 | EP1275392A2 Prolactin inhibiting or stimulating compounds to regulate the immune function |
| 01/15/2003 | EP1275391A1 Pharmaceutical compositions containing irbesartan and a diuretic |
| 01/15/2003 | EP1275390A2 Medicament for treatment of heart failure |
| 01/15/2003 | EP1275389A1 Compositions containing C7 Taxanes |
| 01/15/2003 | EP1275388A1 Tnf- alpha inhibitors |
| 01/15/2003 | EP1275387A1 Fenofibrate pharmaceutical composition with a higher bioavailability and its manufacturing process |
| 01/15/2003 | EP1275386A1 Solid dispersion with improved absorbability |
| 01/15/2003 | EP1275385A1 Remedies for diseases due to stenotic lesions of blood vessel |
| 01/15/2003 | EP1275384A1 Pharmaceutical compositions for oral use, containing, in combination, metformin and glyclazide |
| 01/15/2003 | EP1275383A1 Modified release pharmaceutical composition containing Bupropion HCI as active substance |
| 01/15/2003 | EP1275382A2 Hyperforin as cytostatic agent and hyperforin ointment or cream as application form |
| 01/15/2003 | EP1275381A1 Time-release coated solid compositions for oral administration |
| 01/15/2003 | EP1275379A2 Basic granulate comprising (7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one |
| 01/15/2003 | EP1275377A1 Granulates containing liposoluble substances and process of preparation thereof |
| 01/15/2003 | EP1275376A2 Two-phase hydrogel for application in drops at the eye |
| 01/15/2003 | EP1275375A1 Aerosol compositions |
| 01/15/2003 | EP1275374A1 Buccal, non-polar spray or capsule comprising analgesics or alkaloids |
| 01/15/2003 | EP1275373A1 Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof |
| 01/15/2003 | EP1275308A1 Food composition offering stress relaxation to mammals |
| 01/15/2003 | EP1274980A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 01/15/2003 | EP1274866A2 Diagnosis of diseases associated with metastasis |
| 01/15/2003 | EP1274865A2 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 01/15/2003 | EP1274862A1 Control of a gene induced by oxidized lipids in human artery wall cells |
| 01/15/2003 | EP1274861A1 Compositions and methods for identifying and targeting cancer cells |
| 01/15/2003 | EP1274851A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
| 01/15/2003 | EP1274841A2 Regulation of human cyslt2-like gpcr protein |
| 01/15/2003 | EP1274840A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/15/2003 | EP1274834A1 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |